{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:31:13Z","timestamp":1792009873557,"version":"4.4.0"},"reference-count":147,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The COVID-19 (coronavirus disease 2019) pandemic had an extensive impact on global morbidity and mortality. Several other common respiratory viruses, such as the influenza virus and respiratory syncytial virus (RSV), are endemic or epidemic agents causing acute respiratory infections that are easily transmissible and pose a significant threat to communities due to efficient person-to-person transmission. These viruses can undergo antigenic variation through genetic mutations, resulting in the emergence of novel strains or variants, thereby diminishing the effectiveness of current vaccines, and necessitating ongoing monitoring and adjustment of vaccine antigens. As the virus-specific immunity is maintained only for several weeks or months after the infection, there is an emergent need to develop effective and durable vaccines. Additionally, specific populations, such as elderly or immunocompromised individuals, may exhibit reduced immune responses to respiratory viruses, posing significant challenges to develop vaccines that elicit durable and potent immunity. We present a comprehensive review of the molecular mechanisms underlying the pathogenesis and virulence of common respiratory viruses, such as RSV, influenza virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We discuss several vaccine approaches that are under development. A thorough understanding of the current strategies and the challenges encountered during the vaccine development process can lead to the advancement of effective next-generation vaccines.<\/jats:p>","DOI":"10.3390\/vaccines12080936","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T07:53:37Z","timestamp":1724658817000},"page":"936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vaccines for Respiratory Viruses\u2014COVID and Beyond"],"prefix":"10.3390","volume":"12","author":[{"given":"Kalpana","family":"Rajanala","sequence":"first","affiliation":[{"name":"Ocugen Inc., 11 Great Valley Parkway, Malvern, PA 19355, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1675-1744","authenticated-orcid":false,"given":"Arun Kumar","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Ocugen Inc., 11 Great Valley Parkway, Malvern, PA 19355, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Petrova, V.N., and Russell, C.A. (2018). The evolution of seasonal influenza viruses. Nat. Rev. Microbiol., 16.","DOI":"10.1038\/nrmicro.2017.118"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.onehlt.2015.03.001","article-title":"One health, multiple challenges: The inter-species transmission of influenza A virus","volume":"1","author":"Short","year":"2015","journal-title":"One Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: A modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"ref_4","unstructured":"World Health Organization (2024, August 19). Influenza (Seasonal); Fact Sheet No. 211. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2632010X241228053","DOI":"10.1177\/2632010X241228053","article-title":"The WHO has Declared COVID-19 is No Longer a Pandemic-Level Threat: A Perspective Evaluating Potential Public Health Impacts","volume":"17","author":"Roknuzzaman","year":"2024","journal-title":"Clin. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Saunders-Hastings, P.R., and Krewski, D. (2016). Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and Transmission. Pathogens, 5.","DOI":"10.3390\/pathogens5040066"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Uno, N., and Ross, T.M. (2024). Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-51024-0"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00797-19","DOI":"10.1128\/JVI.00797-19","article-title":"Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs","volume":"93","author":"Dhakal","year":"2019","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/00333549101250S303","article-title":"The 1918-1919 influenza pandemic in the United States: Lessons learned and challenges exposed","volume":"125","author":"Stern","year":"2010","journal-title":"Public Health Rep."},{"key":"ref_11","first-page":"725","article-title":"Vaccination against influenza","volume":"8","author":"Francis","year":"1953","journal-title":"Bull. World Health Organ."},{"key":"ref_12","first-page":"E115","article-title":"History and evolution of influenza control through vaccination: From the first monovalent vaccine to universal vaccines","volume":"57","author":"Barberis","year":"2016","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/irv.12383","article-title":"An overview of the regulation of influenza vaccines in the United States","volume":"10","author":"Weir","year":"2016","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_14","first-page":"43","article-title":"Seasonal influenza vaccines","volume":"333","author":"Fiore","year":"2009","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","article-title":"Live attenuated influenza vaccine (FluMist(R); Fluenz): A review of its use in the prevention of seasonal influenza in children and adults","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.vaccine.2011.01.039","article-title":"Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age","volume":"29","author":"Baxter","year":"2011","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2051013615595595","article-title":"Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults","volume":"3","author":"Cox","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2020.03.017","article-title":"The journey to a respiratory syncytial virus vaccine","volume":"125","author":"Mejias","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Topalidou, X., Kalergis, A.M., and Papazisis, G. (2023). Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens, 12.","DOI":"10.3390\/pathogens12101259"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.coviro.2021.08.010","article-title":"Structure of SARS-CoV-2 spike protein","volume":"50","author":"Zhang","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbiomolbio.2023.02.004","article-title":"An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines","volume":"178","author":"Bayani","year":"2023","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMc2104281","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Roest","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1038\/s41467-021-25982-w","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil","volume":"12","author":"Clemens","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 vaccine candidate appears safe and effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hu, L., Sun, J., Wang, Y., Tan, D., Cao, Z., Gao, L., Guan, Y., Jia, X., and Mao, J. (2023). A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations. Vaccines, 11.","DOI":"10.3390\/vaccines11061045"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"taab051","DOI":"10.1093\/jtm\/taab051","article-title":"Inactivated COVID-19 vaccine BBV152\/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2","volume":"28","author":"Sapkal","year":"2021","journal-title":"J. Travel. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zasada, A.A., Darlinska, A., Wiatrzyk, A., Woznica, K., Forminska, K., Czajka, U., Glowka, M., Lis, K., and Gorska, P. (2023). COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic. Viruses, 15.","DOI":"10.3390\/v15091786"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbamem.2013.10.004","article-title":"Receptor binding and pH stability\u2014How influenza A virus hemagglutinin affects host-specific virus infection","volume":"1838","author":"Mair","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.12688\/f1000research.9637.1","article-title":"Respiratory syncytial virus infection: An innate perspective","volume":"5","author":"Johansson","year":"2016","journal-title":"F1000Research"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Johnson, S.M., McNally, B.A., Ioannidis, I., Flano, E., Teng, M.N., Oomens, A.G., Walsh, E.E., and Peeples, M.E. (2015). Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005318"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41579-021-00542-7","article-title":"Influenza virus and SARS-CoV-2: Pathogenesis and host responses in the respiratory tract","volume":"19","author":"Flerlage","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10950","DOI":"10.1128\/JVI.05992-11","article-title":"Filamentous influenza virus enters cells via macropinocytosis","volume":"86","author":"Rossman","year":"2012","journal-title":"J. Virol."},{"key":"ref_43","first-page":"3","article-title":"Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhang, Y.Y., Liang, R., Wang, S.J., Ye, Z.W., Wang, T.Y., Chen, M., Liu, J., Na, L., Yang, Y.L., and Yang, Y.B. (2022). SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.102511"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1743-422X-5-127","article-title":"Respiratory syncytial virus glycoproteins uptake occurs through clathrin-mediated endocytosis in a human epithelial cell line","volume":"5","year":"2008","journal-title":"Virol. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1111\/febs.15369","article-title":"Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing","volume":"287","author":"Glebov","year":"2020","journal-title":"FEBS J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.micinf.2004.05.002","article-title":"Endocytosis of influenza viruses","volume":"6","author":"Lakadamyali","year":"2004","journal-title":"Microbes Infect."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Aganovic, A. (2023). pH-dependent endocytosis mechanisms for influenza A and SARS-coronavirus. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1190463"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Verma, D.K., Gupta, D., and Lal, S.K. (2018). Host Lipid Rafts Play a Major Role in Binding and Endocytosis of Influenza A Virus. Viruses, 10.","DOI":"10.3390\/v10110650"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2011.10.029","article-title":"Cholesterol-rich lipid rafts are required for release of infectious human respiratory syncytial virus particles","volume":"422","author":"Chang","year":"2012","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Palacios-R\u00e1palo, S.N., De Jes\u00fas-Gonz\u00e1lez, L.A., Cordero-Rivera, C.D., Farfan-Morales, C.N., Osuna-Ramos, J.F., Mart\u00ednez-Mier, G., Quisti\u00e1n-Galv\u00e1n, J., Mu\u00f1oz-P\u00e9rez, A., Bernal-Dolores, V., and Del \u00c1ngel, R.M. (2021). Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.796855"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Dou, D., Revol, R., Ostbye, H., Wang, H., and Daniels, R. (2018). Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01581"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: Challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bergeron, H.C., and Tripp, R.A. (2022). RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein. Viruses, 14.","DOI":"10.3390\/v14112396"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"31642","DOI":"10.1074\/jbc.M102633200","article-title":"Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences","volume":"276","author":"Zimmer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","article-title":"Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design","volume":"23","author":"Malone","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gu, Y., Zuo, X., Zhang, S., Ouyang, Z., Jiang, S., Wang, F., and Wang, G. (2021). The Mechanism behind Influenza Virus Cytokine Storm. Viruses, 13.","DOI":"10.3390\/v13071362"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Park, J.H., and Lee, H.K. (2021). Delivery Routes for COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9050524"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41590-021-00870-z","article-title":"Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity","volume":"22","author":"Flament","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Carvajal, J.J., Avellaneda, A.M., Salazar-Ardiles, C., Maya, J.E., Kalergis, A.M., and Lay, M.K. (2019). Host Components Contributing to Respiratory Syncytial Virus Pathogenesis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02152"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1473-3099(13)70286-X","article-title":"Pathogenesis of influenza-induced acute respiratory distress syndrome","volume":"14","author":"Short","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Jackson, L.A., Gaglani, M.J., Keyserling, H.L., Balser, J., Bouveret, N., Fries, L., and Treanor, J.J. (2010). Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: A randomized, placebo-controlled trial over two influenza seasons. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-71"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.-G. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 9.","DOI":"10.3390\/vaccines9121490"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.282.2.137","article-title":"Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial","volume":"282","author":"Nichol","year":"1999","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1016\/j.vaccine.2021.08.018","article-title":"Could live attenuated vaccines better control COVID-19?","volume":"39","author":"Okamura","year":"2021","journal-title":"Vaccine"},{"key":"ref_72","first-page":"259","article-title":"Live-attenuated respiratory syncytial virus vaccines","volume":"372","author":"Karron","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e023118","DOI":"10.1136\/bmjopen-2018-023118","article-title":"Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: A population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink","volume":"8","author":"Caspard","year":"2018","journal-title":"BMJ Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2016.08.018","article-title":"Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories","volume":"34","author":"Rudenko","year":"2016","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/infdis\/jiaa049","article-title":"Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children","volume":"221","author":"McFarland","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"312ra175","DOI":"10.1126\/scitranslmed.aac8463","article-title":"A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children","volume":"7","author":"Karron","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2017.03.015","article-title":"Ongoing developments in RSV prophylaxis: A clinician\u2019s analysis","volume":"24","author":"Rezaee","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","article-title":"Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/intimm\/dxab061","article-title":"Humoral and cellular immunity and the safety of COVID-19 vaccines: A summary of data published by 21 May 2021","volume":"33","author":"Xu","year":"2021","journal-title":"Int. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-022-00509-6","article-title":"Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2","volume":"7","author":"Tioni","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: What you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Scorza, F.B., and Pardi, N. (2018). New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines, 6.","DOI":"10.3390\/vaccines6020020"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eimc.2021.07.009","article-title":"The new generation of messenger RNA (mRNA) vaccines against influenza","volume":"41","author":"Reina","year":"2023","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Echaide, M., Chocarro de Erauso, L., Bocanegra, A., Blanco, E., Kochan, G., and Escors, D. (2023). mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065944"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/d41573-021-00176-7","article-title":"mRNA flu shots move into trials","volume":"20","author":"Dolgin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_89","first-page":"1365","article-title":"Moderna\u2019s mRNA Vaccine for Seasonal Flu Enters Clinical Trials","volume":"326","author":"Abbasi","year":"2021","journal-title":"JAMA"},{"key":"ref_90","first-page":"1784","article-title":"Pfizer Launches Phase 1 mRNA Flu Vaccine Trial","volume":"326","author":"Abbasi","year":"2021","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/s41467-022-32149-8","article-title":"Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses","volume":"13","author":"Pardi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines","volume":"325","author":"Gee","year":"2021","journal-title":"JAMA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41569-021-00662-w","article-title":"Myocarditis after COVID-19 mRNA vaccination: Clinical observations and potential mechanisms","volume":"19","author":"Heymans","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-024-00893-1","article-title":"Myocarditis associated with COVID-19 vaccination","volume":"9","author":"Buoninfante","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Heidary, M., Kaviar, V.H., Shirani, M., Ghanavati, R., Motahar, M., Sholeh, M., Ghahramanpour, H., and Khoshnood, S. (2022). A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.927306"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/pch\/8.10.605","article-title":"Respiratory syncytial virus vaccine: Is it coming?","volume":"8","author":"Sales","year":"2003","journal-title":"Paediatr. Child. Health"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chen, J., Wang, J., Zhang, J., and Ly, H. (2021). Advances in Development and Application of Influenza Vaccines. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.711997"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMp038238","article-title":"Influenza vaccine\u2014Outmaneuvering antigenic shift and drift","volume":"350","author":"Treanor","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: Immunology, application, and optimization","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"101020","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): The interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.53854\/liim-2903-3","article-title":"Review of COVID-19 viral vector-based vaccines and COVID-19 variants","volume":"29","author":"Vanaparthy","year":"2021","journal-title":"Infez. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e140794","DOI":"10.1172\/JCI140794","article-title":"A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","volume":"131","author":"Matsuda","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Sayedahmed, E.E., Elkashif, A., Alhashimi, M., Sambhara, S., and Mittal, S.K. (2020). Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines8040574"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Butler, C., Ellis, C., Folegatti, P.M., Swayze, H., Allen, J., Bussey, L., Bellamy, D., Lawrie, A., Eagling-Vose, E., and Yu, L.M. (2021). Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS). Vaccines, 9.","DOI":"10.3390\/vaccines9080851"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/infdis\/jiac481","article-title":"Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age","volume":"227","author":"Epalza","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/infdis\/jiad108","article-title":"Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine","volume":"228","author":"Jordan","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Falsey, A.R., Hosman, T., Bastian, A.R., Vandenberghe, S., Chan, E.K.H., Douoguih, M., Heijnen, E., Comeaux, C.A., Callendret, B., and on behalf of the CYPRESS Investigators (2024). Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): A randomised, double-blind, placebo-controlled, phase 2b study. Lancet Infect. Dis.","DOI":"10.1016\/S1473-3099(24)00226-3"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: Mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: Putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Verma, S.K., Mahajan, P., Singh, N.K., Gupta, A., Aggarwal, R., Rappuoli, R., and Johri, A.K. (2023). New-age vaccine adjuvants, their development, and future perspective. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1043109"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"102229","DOI":"10.1016\/j.coi.2022.102229","article-title":"Resolving adjuvant mode of action to enhance vaccine efficacy","volume":"77","author":"Turley","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41541-021-00418-0","article-title":"\u201cWorld in motion\u201d\u2014Emulsion adjuvants rising to meet the pandemic challenges","volume":"6","author":"Lodaya","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41541-021-00337-0","article-title":"Antibody avidity, persistence, and response to antigen recall: Comparison of vaccine adjuvants","volume":"6","author":"Budroni","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: Opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(21)00192-4","article-title":"Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: A phase 3 randomised controlled trial","volume":"22","author":"Shinde","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2189885","DOI":"10.1080\/21645515.2023.2189885","article-title":"The Matrix-M adjuvant: A critical component of vaccines for the 21(st) century","volume":"19","author":"Stertman","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"109006","DOI":"10.1016\/j.isci.2024.109006","article-title":"Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture","volume":"27","author":"Lv","year":"2024","journal-title":"iScience"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Coleman, B.L., Gutmanis, I., McGovern, I., and Haag, M. (2023). Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis. Vaccines, 11.","DOI":"10.3390\/vaccines11101607"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Rockman, S., Laurie, K., Ong, C., Rajaram, S., McGovern, I., Tran, V., and Youhanna, J. (2023). Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines, 11, Erratum in Vaccines 2023, 11, 1839.","DOI":"10.3390\/vaccines11121839"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"20748","DOI":"10.1073\/pnas.1113801108","article-title":"Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses","volume":"108","author":"Sandbulte","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Bezbaruah, R., Deka, K., Nongrang, L., and Kalita, T. (2022). The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines, 10.","DOI":"10.3390\/vaccines10111926"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vaccine.2022.11.014","article-title":"Misinformation and COVID-19 vaccine hesitancy","volume":"41","author":"Zimmerman","year":"2023","journal-title":"Vaccine"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Russell, M.W., Moldoveanu, Z., Ogra, P.L., and Mestecky, J. (2020). Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.611337"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.immuni.2022.04.013","article-title":"Mucosal immune responses to infection and vaccination in the respiratory tract","volume":"55","author":"Mettelman","year":"2022","journal-title":"Immunity"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Dotiwala, F., and Upadhyay, A.K. (2023). Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens. Vaccines, 11.","DOI":"10.3390\/vaccines11101585"},{"key":"ref_142","first-page":"107","article-title":"The systemic and mucosal immune response of humans to influenza A virus","volume":"146","author":"Murphy","year":"1989","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: The promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri1370","article-title":"Therapeutic potential of oral tolerance","volume":"4","author":"Mayer","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(23)00049-8","article-title":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: A multicentre, open-label, phase 4, randomised trial","volume":"11","author":"Tang","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin((R)))","volume":"8","author":"Singh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"102370","DOI":"10.1016\/j.coi.2023.102370","article-title":"Viral-vectored respiratory mucosal vaccine strategies","volume":"84","author":"Jeyanathan","year":"2023","journal-title":"Curr. Opin. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:40:48Z","timestamp":1760110848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":147,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["vaccines12080936"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12080936","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}